Hepatocellular Carcinoma
Conditions
Interventions
single arm:Oral apatinib combined with continuous hepatic arterial infusion of oxaliplatin and raltitrexed
Sponsors
Fujian Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Ages 18 to 70 years, (2) The diagnosis of hepatocellular carcinoma based on the recommendation of the American Association for the Study of Liver Diseases, (3) The patient should be a BCLC stage C patient with extrahepatic metastasis, and a person who has progressed or is unable to receive molecular targeted drug therapy such as Solafini. (4) When entering the study, the patient should be stopped for more than 4 weeks. (5) There is at least one measurable lesion that meets the RECIST v1.1 standard; (6) Child-Pugh class: A or B. (7) ECOG score 0-2. (8) An estimated survival period of more than 2 months. (9) Bone marrow function (hemoglobin >= 10 g/dL, leukocyte >= 3,000µL, platelet>= 75,000µL), liver function (bilirubin <= 3 mg/dL, aminotransferase <= 200 U/L), kidney function (muscle liver <= 390µmol/L). The coagulation function is basically normal.
Exclusion criteria
Exclusion criteria: (1) Decompensation of liver function (including uncontrolled ascites, hepatic encephalopathy, acute or recent gastrointestinal bleeding within 2 weeks). (2) Acute infection or sepsis. (3) During pregnancy. (4) Patients with cardiac insufficiency or poor lung function. (5) The life expectancy is less than three months. (6) Brain metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor response; | — |
Countries
China
Contacts
Public ContactShiguang Chen
Fujian Cancer Hospital
Outcome results
None listed